gabapentin enacarbil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| gabamimetic agents | 4177 | 478296-72-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Gabapentin enacarbil is a prodrug of gabapentin and, accordingly, its therapeutic effects in restless legs syndrome and postherpetic neuralgia are attributable to gabapentin. In animal models of analgesia, gabapentin prevents allodynia (pain-related behavior in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 0.50 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 6, 2011 | FDA | XENOPORT INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 950.04 | 34.62 | 317 | 1365 | 246933 | 63240407 |
| Completed suicide | 439.68 | 34.62 | 158 | 1524 | 145515 | 63341825 |
| Cardio-respiratory arrest | 164.19 | 34.62 | 61 | 1621 | 59898 | 63427442 |
| Drug abuse | 145.95 | 34.62 | 59 | 1623 | 72459 | 63414881 |
| Accidental overdose | 111.35 | 34.62 | 36 | 1646 | 23273 | 63464067 |
| Myoclonus | 42.72 | 34.62 | 16 | 1666 | 15852 | 63471488 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 790.59 | 52.21 | 262 | 708 | 200100 | 34755861 |
| Completed suicide | 324.93 | 52.21 | 115 | 855 | 98053 | 34857908 |
| Drug abuse | 175.09 | 52.21 | 74 | 896 | 99022 | 34856939 |
| Cardio-respiratory arrest | 119.95 | 52.21 | 48 | 922 | 55225 | 34900736 |
| Accidental overdose | 59.60 | 52.21 | 22 | 948 | 20118 | 34935843 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Toxicity to various agents | 1725.39 | 33.90 | 578 | 1784 | 420962 | 79321064 |
| Completed suicide | 735.59 | 33.90 | 272 | 2090 | 245495 | 79496531 |
| Drug abuse | 316.64 | 33.90 | 133 | 2229 | 162558 | 79579468 |
| Cardio-respiratory arrest | 280.72 | 33.90 | 109 | 2253 | 108401 | 79633625 |
| Accidental overdose | 189.99 | 33.90 | 63 | 2299 | 39518 | 79702508 |
| Myoclonus | 79.02 | 33.90 | 30 | 2332 | 27630 | 79714396 |
| Intentional product misuse | 36.95 | 33.90 | 27 | 2335 | 95138 | 79646888 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D018692 | Antimanic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018691 | Excitatory Amino Acid Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D014149 | Tranquilizing Agents |
| FDA EPC | N0000175753 | Anti-epileptic Agent |
| CHEBI has role | CHEBI:35623 | anticonvulsants |
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:38215 | calcium channel blockers |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
| CHEBI has role | CHEBI:50266 | Prodrugs |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postherpetic neuralgia | indication | 2177002 | |
| Restless legs | indication | 32914008 | DOID:0050425 |
| Partial Epilepsy Treatment Adjunct | off-label use | ||
| Suicidal thoughts | contraindication | 6471006 | |
| Depressive disorder | contraindication | 35489007 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.33 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8686034 | Jan. 24, 2025 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8686034 | Jan. 24, 2025 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8686034 | Jan. 24, 2025 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8686034 | Jan. 24, 2025 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8114909 | April 11, 2026 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8114909 | April 11, 2026 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 300MG | HORIZANT | AZURITY | N022399 | Dec. 13, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| 600MG | HORIZANT | AZURITY | N022399 | April 6, 2011 | RX | TABLET, EXTENDED RELEASE | ORAL | 8795725 | June 10, 2029 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent calcium channel subunit alpha-2/delta-1 | Ion channel | MODULATOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||||
| Voltage-dependent calcium channel subunit alpha-2/delta-2 | Ion channel | MODULATOR | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| 4030724 | VUID |
| N0000182734 | NUI |
| D09539 | KEGG_DRUG |
| 4020833 | VANDF |
| 4030724 | VANDF |
| C2700226 | UMLSCUI |
| CHEBI:68840 | CHEBI |
| CHEBI:42797 | CHEBI |
| GBN | PDB_CHEM_ID |
| CHEMBL1628502 | ChEMBL_ID |
| DB08872 | DRUGBANK_ID |
| C493250 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7560 | IUPHAR_LIGAND_ID |
| 8611 | INN_ID |
| 75OCL1SPBQ | UNII |
| 9883933 | PUBCHEM_CID |
| 1095698 | RXNORM |
| 180816 | MMSL |
| 27821 | MMSL |
| 4770 | MMSL |
| 60712 | MMSL |
| d03182 | MMSL |
| 004415 | NDDF |
| 013726 | NDDF |
| 108402001 | SNOMEDCT_US |
| 386845007 | SNOMEDCT_US |
| 703122000 | SNOMEDCT_US |
| C0060926 | UMLSCUI |
| DB00996 | DRUGBANK_ID |
| 5094 | INN_ID |
| D000077206 | MESH_DESCRIPTOR_UI |
| 3446 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0101 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | NDA | 35 sections |
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0101 | TABLET, EXTENDED RELEASE | 600 mg | ORAL | NDA | 35 sections |
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0103 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | NDA | 35 sections |
| Horizant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53451-0103 | TABLET, EXTENDED RELEASE | 300 mg | ORAL | NDA | 35 sections |